A Phase I, Open-Label, Parallel-Group, Single-Dose Study to Assess the Pharmacokinetics of XL184 (Cabozantinib) Capsules in Hepatic Impaired Adult Subjects

Trial Profile

A Phase I, Open-Label, Parallel-Group, Single-Dose Study to Assess the Pharmacokinetics of XL184 (Cabozantinib) Capsules in Hepatic Impaired Adult Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Sep 2016

At a glance

  • Drugs Cabozantinib (Primary)
  • Indications Acute myeloid leukaemia; Breast cancer; Cancer; Cholangiocarcinoma; Liver cancer; Male breast cancer; Merkel cell carcinoma; Multiple myeloma; Non-small cell lung cancer; Ovarian cancer; Prostate cancer; Renal cancer; Solid tumours; Thyroid cancer; Urogenital cancer
  • Focus Pharmacokinetics
  • Sponsors Exelixis
  • Most Recent Events

    • 21 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 18 Apr 2014 Status changed from recruiting to active, no longer recruiting, as per ClinicalTrials.gov record.
    • 26 Feb 2013 Planned end date changed from 1 Sep 2012 to 1 Dec 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top